Double-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells (PRS CK STORM) in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
Overview
- Phase
- Phase 1
- Intervention
- Placebo comparator
- Conditions
- Not specified
- Sponsor
- PEACHES BIOTECH
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Adverse Events (AEs)
- Status
- Recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of Monocytes and fat-derived Mesenchymal Stromal Cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of the acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV) in recently hospitalized participants (less than 3 days) in need for oxygen therapy.
The main questions it aims to answer are:
- Are both doses of PRS CK STORM (dose A and dose B) safe as an intravenous drug to modulate inflammatory processes, such as the cytokine storm for the treatment of ARDS caused by SARS-Cov-2, influenza A, influenza B and RSV?
- Are both doses of PRS CK STORM (dose A and dose B) effective as an intravenous drug to modulate ARDS-associated cytokine storm caused by SARS-Cov-2, influenza A, influenza B and RSV compared to the control group?
- What are the anti-inflammatory and pro-inflammatory cytokine profiles after treatment with two different doses of PRS CK STORM in participants hospitalized for ARDS caused by SARS-Cov-2, influenza A, influenza B and RSV?
Researchers will compare both doses of PRS CK STORM with the control group to test whether the anti-inflammatory action of PRS CK STORM is safe and effective in modulating the cytokine storm for the treatment of ARDS caused by SARS-Cov-2, influenza A, influenza B and RSV. In addition, the anti-inflammatory and pro-inflammatory cytokine profiles after treatment PRS CK STORM compared to placebo group in these participants will be also studied.
Detailed Description
This is a double-blind, randomized, phase I/II pilot clinical trial of two doses of PRS CK STORM in hospitalized adult participants with ARDS caused by SARS-Cov-2, influenza A, influenza B and RSV All participants will receive the standard of care for ARDS, according to its viral origin: * Clinical management of COVID-19: hospital care (Centro de Coordinación de Alertas y Emergencias Sanitarias, 2020). * Clinical practice guidelines for influenza (WHO, 2024). Participants who meet the eligibility criteria will be randomized in blocks to reach the 2:2:1 ratio (dose A: dose B: placebo). This study consists of two parts: Part 1: Two different doses (A and B) of PRS CK STORM will be evaluated in 2 groups of 4 participants (3:1; PRS CK STORM: placebo). It starts with a first sentinel group of 4 participants who will be assigned to placebo or study drug dose A. First, only 2 participants will randomly be assigned to receive the active treatment of dose A or placebo for 5 consecutive days. These 2 first participants will be followed up to 48h after the last drug administration (short-term safety follow-up period) when a safety assessment will be completed before treating the other 2 participants in this group. If the study drug is considered safe during the short-term safety assessment planned 48h after the last drug administration, then 2 additional participants will be treated with dose A for 5 consecutive days to complete the first sentinel group of 4 participants. These 2 participants will be followed up to 48h after the last study drug administration before moving to dose B. After the assessment of data collected follow-up for this first group, a second small sentinel group of other 4 participants will be treated with a higher dosage (dose B) following the same process: firstly, only 2 participants will randomly receive the active treatment of dose B or placebo for 5 consecutive days and then these 2 first participants will be followed up to 48h after. If the study drug is considered safe during the safety assessment planned 48h after last drug administration, then two additional participants will be treated with dose B for 5 consecutive days to complete the sentinel second group of 4 participants evaluating dose B. These 2 participants will be also followed up to 48h after the last study drug administration before moving to Part 2. All these 8 participants included in Part 1 will continue in a long-term safety follow-up period until 1 year post treatment. Part 2: 42 additional participants will be treated for 5 consecutive days. These 42 participants will be randomized to three treatment arms: 17 in the active arm with dose A, 17 participants in the active arm with dose B and 8 participants in the placebo arm. All participants in Part 2 will be followed up to 48h after the last study drug (short-term safety follow-up period). Once all participants treated in Part 2 finished the short-term safety follow-up period (48h after last study drug administration), all data will be verified and statistically analyzed in an interim analysis. All participants will be followed up to 1 year post treatment (long-term safety follow-up period). Therefore, considering the participants enrolled in Part 1 and Part 2 the total number of participants for safety, tolerability and efficacy analysis will be 50 assigned to three different arms (total randomization ratio 2:2:1), 20 participants will receive dose A, 20 participants will receive dose B and 10 participants will receive placebo. To sum up, considering the participants enrolled in Part 1 and Part 2 the total number of participants for safety, tolerability and efficacy analysis will be 50 assigned to three different arms (total randomization ratio 2:2:1), 20 participants will receive dose A of PRS CK STORM, 20 participants will receive dose B of PRS CK STORM and 10 participants will receive placebo. The estimated duration of the study for individual participants will be 12 months (screening: 3 days, treatment period: 5 days, short-term safety follow-up period: 2 days after the last drug intake and long-term safety follow-up period: up to 48 weeks from randomization). It is hypothesized that both doses of PRS CK STORM for intravenous administration are safe, well tolerated and clinically beneficial versus placebo for participants with ARDS-associated cytokine storm.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent by the patient or legal representative prior to the initiation of any study-specific procedure.
- •Males and females aged ≥ 18 years old at the time of the consent.
- •Hospitalized patients with a diagnosis of ARDS confirmed by Berlin criteria.
- •Confirmed diagnosis of SARS-CoV-2, influenza virus A, influenza virus B or RSV pneumonia by positive RT-PCR (results of a PCR prior to screening will be valid only if the PCR has been done for all 4 viruses and in 3 days prior to the screening visit). PCR will include the analysis of SARS-Cov-2, influenza A, influenza B and RSV.
- •Diagnosis of systemic inflammatory response syndrome (SIRS), defined by the satisfaction of any two of the criteria below:
- •Body temperature over 38 ºC or under 36 ºC.
- •Heart rate greater than 90 beats/minute.
- •Respiratory rate higher than 20 breaths/min or PaCO2 lower than 32 mmHg.
- •Leukocyte count higher than 12000/μL, lower than 4000/μL or over 10% immature forms or bands.
- •Need for oxygen therapy.
Exclusion Criteria
- •Failure to perform screening or baseline examinations.
- •Body Mass Index (BMI) more than or equal to
- •Irreversible critical condition.
- •Active autoimmune diseases or severe immunosuppression.
- •Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations, may bias the clinical assessment, such as:
- •Liver function test abnormalities or other signs of hepatic insufficiency: Aspartate transaminase (AST), alanine transaminase (ALT) more than 3 per upper limit of the reference range, total bilirubin more than or equal to 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin relating to Gilbert syndrome.
- •Renal insufficiency (serum creatinine more than 2 mg/dL (more than 150 μmol/L) and creatinine clearance less than 60 (according to Cockcroft-Gault formula).
- •Myocardial infarction, unstable angina, heart failure within 3 months before screening.
- •Bradycardia (heartbeat less than 50/min).
- •Atrioventricular block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcF interval (males more than 450 msec and females more than 470 msec using Fridericia's formula: QTc = QT/ RR\^2 ).
Arms & Interventions
Saline Solution 0,9% for injection
Participants will receive a single 10 mL dose Intravenous (IV) infusion of normal saline (0.9%)
Intervention: Placebo comparator
PRS CK STORM - dose A
A sterile secretome derived from the co-culture of M2-type macrophages and ASC (adipose stromal cells) containing 116,059 pg/mL Tissue Inhibitor of Matrix Metalloproteinase- 1 (TIMP-1). Participants will receive a total dose of 1,160,585.366 pg of TIMP-1 via IV infusion
Intervention: PRS CK STORM
PRS CK STORM - dose B
A sterile secretome derived from the co-culture of M2-type macrophages and ASC (adipose stromal cells) containing 232,017 pg/mL TIMP-1. Participants will receive a total dose of 1,160,585.366 pg of TIMP-1 via IV infusion.
Intervention: PRS CK STORM
Outcomes
Primary Outcomes
Adverse Events (AEs)
Time Frame: Up to 12 months
Number and proportion of subjects experiencing AEs.
Serious adverse events (SAEs)
Time Frame: Up to 12 months
Number and proportion of subjects experiencing SAEs
Treatment-emergent adverse events (TEAEs)
Time Frame: Up to 12 months
Number and proportion of subjects experiencing TEAEs
Safety measures: Clinical evaluation through physical examination
Time Frame: Day 7, Day 30, Day 90 and Day 365
Number and proportion of subjects with abnormal findings of physical examination parameters (head, ears, Nervous system,Gastrointestinal system, Respiratory system, Lymph nodes Musculoskeletal system, Neck, Throat, Cardiovascular system, Skin, Nose) will be evaluated
Changes from Baseline in vital signs: body temperature
Time Frame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
Body Temperature of participants will be measure d in Celsius (ºC)
Changes from Baseline in vital signs: oximetry
Time Frame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
Levels of blood oxygen saturation (SpO2) using a pulse oximeter will be measured in percentage
Changes from Baseline in vital signs: Heart rate
Time Frame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
Heart rate will be measured as number of beats per minute (bpm)
Changes from Baseline in vital signs: Respiratory rate
Time Frame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
Respiratory rate will be measured as number of breaths taken per minute (Breaths/min) .
Changes from Baseline in vital signs: Diastolic Blood Pressure
Time Frame: From Day 1 to Day 7, Day 30, Day 90 and Day 365
Diastolic blood pressure will be measured in mmHg
Changes from Baseline in vital signs: Systolic blood pressure
Time Frame: : From Day 1 to Day 7, Day 30, Day 90 and Day 365
Systolic blood pressure will be measured in mmHg
Safety measures: electrocardiograms (ECG)
Time Frame: Day 7, Day 30, Day 90 and Day 365
Cardiac dysfunction will be monitored by 12-lead ECGs. Abnormal or normal readings will be evaluated
Safety measures: Laboratory results
Time Frame: Day 1, Day 3, Day 6, Day 7, Day 30, Day 90 and Day 365
Abnormal or normal laboratory test results (biochemistry, hematology, coagulation, and urinalysis) will be evaluated
Secondary Outcomes
- Severity of ARDS(Up to 12 months)
- Death rate(Day 7, Day 14 and Day 365)
- Average hospital stays (in days)(Up to 12 months)
- Participants requiring admission to Intensive Care Unit (ICU)(Up to 12 months)
- Duration of ICU stay(Up to 12 months)
- Thorax radiological findings(Day 7 and Day 10 Up to 12 months)
- Oximetry levels(Up to 12 months)
- Overall survival (in days)(Up to 12 months)
- Time to progression (in days)(Up to 12 months)
- Need for invasive mechanical ventilation(Up to 12 months)
- Time to invasive mechanical ventilation (in days)(Up to 12 months)